Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IBIO
Strong SellSinkeriBio, Inc. · Healthcare · United States · $68M · Avg Vol: $850K/d
3
StockRankGet insider-trade alerts
Q
22
V
33
M
11
P/E (TTM)
—
ROE
-65.7%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.9M | 0 | 0.2M | 0.4M | -40.3% | 0.1M | 28.6K | 25.0K | -60.3% |
| EPS | -1.02 | -2.17 | -1.13 | -0.68 | — | -0.32 | -0.32 | -0.46 | — |
| Shares | 49.7M | 49.7M | 49.7M | 49.7M | 0.0% | 64.3M | — | — | — |
| Debt | 25.8M | 17.1M | 4.5M | 3.5M | -48.6% | 2.2M | — | — | — |
| Equity | 63.5M | 15.4M | 21.3M | 14.9M | -38.3% | — | — | — | — |
| Op CF | -37.5M | -30.4M | -18.6M | -15.3M | — | -23.2M | — | — | — |
| Inv CF | -5.1M | 7.0M | 0.9M | 0.7M | — | — | — | — | — |
| Fin CF | -6.1M | 2.3M | 24.5M | 8.9M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-7.4%
SMA 50SMA 200
Close
$1.26
RSI (14)
24.4
52W High
$3.82
From 52W High
0.3%
SCORE BREAKDOWN
Quality
22
ROIC
-160.8%3.7
ROE
-65.7%15.0
GP/Assets
0.4%11.5
Op. Margin
-30138.0%1.4
FCF/Assets
-95.6%2.3
Piotroski
439.0
Int. Cover
-50.0x5.9
D/E Ratio
0.03x77.6
Current Ratio
7.85x83.1
Value
33
P/E (TTM)
—N/A
EV/EBITDA
0.1x25.0
P/FCF
—N/A
P/B
0.6x95.1
P/S
842.4x2.5
Div Yield
—N/A
Momentum
11
52W High %
33%8.8
RS 6M
-60%8.6
SMA 50/200
0.78x13.7
EPS Rev 4W
-47.6%1.2
EPS Rev 12W
—N/A
EPS Improve
-43%10.3
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$68M
P/E (Forward)
-2.9x
Gross Margin
100.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IBIO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IBIO | iBio, Inc.(you) | $68M | 3 | Strong Sell |
| RNTX | Rein Therapeutics Inc. | $66M | 2 | Strong Sell |
| EXOZ | eXoZymes, Inc. | $67M | 2 | Strong Sell |
| ELTX | Elicio Therapeutics, Inc. | $75M | 2 | Strong Sell |
| ESLA | Estrella Immunopharma, Inc. | $62M | 1 | Strong Sell |
| FLNA | Filana Therapeutics, Inc. | $58M | 4 | Strong Sell |
| GOSS | Gossamer Bio, Inc. | $83M | 2 | Strong Sell |
| CRDF | Cardiff Oncology, Inc. | $73M | 6 | Strong Sell |
| HRTX | Heron Therapeutics, Inc. | $62M | 7 | Strong Sell |
| KALA | KALA BIO, Inc. | $63M | 7 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%